

ORAL PRESENTATION

Open Access

High-Gd-Payload P22 protein cage nanoparticles for imaging vascular inflammation

Hisanori Kosuge^{1*}, Masaki Uchida², Janice Lucon², Shefah Qazi², Trevor Douglas², Michael V. McConnell¹

From 16th Annual SCMR Scientific Sessions
San Francisco, CA, USA. 31 January - 3 February 2013

Background

The bacteriophage P22 protein cage can be bioengineered to contain a high-relaxivity gadolinium (Gd) payload internally and targeting ligands externally. It also enables phage-library-based identification of novel targets. Thus, P22 may have advantages for molecular/cellular imaging by MRI.

Methods

1) P22: The P22 protein cage (60 nm) is bioengineered with an internal polymer network with amine functional groups allowing incorporation of ~9100 Gd-DTPA molecules per cage via the amine groups (Figure 1: [1]). This provides a per cage relaxivity of $70000 \text{ mM}^{-1}\text{s}^{-1}$, superior to Gd-DTPA for the equivalent Gd concentration.


2) Atherosclerosis Models: Both ApoE-deficient (ApoE^{-/-}) and FVB mice were used. ApoE^{-/-} mice develop atherosclerosis enhanced by high-fat diet. FVB mice develop macrophage-rich carotid lesions with carotid ligation in combination with high-fat diet and diabetes induction [2].

3) P22-polymer-Gd *in vivo* MR imaging: Mice were injected intravenously with P22-polymer-Gd (N=5, 20 μmol Gd/kg, one-fifth the typical clinical dose) or Magnevist (N=1, 20 μmol Gd/kg). Vascular MRA at 1T was performed (Aspect M2TM, 500 mT/m, 2500 T/m/s) using 3D-SPGR (TR/TE=12 ms/2.1 ms, slice thickness=1 mm, FOV=5 cm, matrix=128x128, FA=45). Vessel wall MRI at 3T was performed (Signa HDx, GE Healthcare, 50mT/m, 150 T/m/s) with a phased-array mouse coil (RAPID MR International), using a double inversion recovery fast spin echo sequence (TR/TE= 400 ms/15 ms, slice thickness=1mm, FOV=3 cm, matrix= 256x256) up to 24 hours after injection.

4) RGD-targeted P22 *ex vivo* fluorescence imaging: Molecular targeting of P22 was evaluated by attaching RGD peptides externally, which targets the $\alpha\text{V}\beta3$ integrin, upregulated on activated macrophages. ApoE^{-/-} mice (N=4) were injected intravenously with RGD⁺P22 or RGD⁻P22 (labeled with Cy5.5, 4 nmol/mouse). Forty-eight hours later, *ex vivo* fluorescence imaging was performed using MaestroTM imaging system (Cri, Woburn, MA). Maximum plaque signal intensities were measured and compared.

Results

Low dose P22-polymer-Gd showed strong enhancement for 1T vascular MRA (Figure 2). It also showed clear enhancement of the aortic wall (ApoE^{-/-}) and ligated carotid (FVB) at 3T (Figure 3). *Ex vivo* fluorescence imaging showed the accumulation of both RGD⁺P22 or RGD⁻P22 in atherosclerotic lesions (Figure 4). RGD targeting enhanced plaque uptake (RGD⁺P22: 0.025 ± 0.002 counts/sec vs. RGD⁻P22: 0.005 ± 0.004 counts/sec, $p=0.05$).



¹Stanford University, Stanford, CA, USA
Full list of author information is available at the end of the article




Figure 2




Figure 3

Conclusions

The P22 protein cage nanoparticle demonstrates both internal high-relaxivity Gd-loading for *in vivo* MRI as well as external RGD-targeting for enhanced uptake in vascular inflammation. Thus, P22 is a novel, multi-functional nanoparticle platform for targeted-imaging of atherosclerosis.

Funding

GE healthcare, Kowa, Inc.

Author details

¹Stanford University, Stanford, CA, USA. ²Montana State University, Bozeman, MT, USA.




Figure 4

Published: 30 January 2013

References

1. Lucon J, et al. . *Nat Chem* 2012, **4**:781-788.
2. Kosuge , et al. . *PLoS One* 2011, **6**:e14523.

doi:10.1186/1532-429X-15-S1-O66

Cite this article as: Kosuge et al.: High-Gd-Payload P22 protein cage nanoparticles for imaging vascular inflammation. *Journal of Cardiovascular Magnetic Resonance* 2013 **15**(Suppl 1):O66.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

